According to a long-term study conducted over ten years, Indian stent, Yukon Choice PC and Supra Flex, were ‘equally good’ as that of Abbott’s Xience, as reported by Times Of India (TOI).
Abbott, the American multinational healthcare company, leads the market for stents.
The study based on the extended survey of 2,603 patients was published in the journal of AHA (American Heart Association).
In February 2017, Indian government had capped the prices of stents which led to a price reduction of almost 75 per cent. Following this, several multinational companies had threatened to withdraw their stents from the market. In April 2018, Abbott had discontinued selling Xience Alpine Premium stents in India.
The foreign manufacturers claimed that their products were superior to Indian counterparts and therefore deserved a higher price. All these claims stand discredited by the new study.
“We are excited with this first long-term data which is a new milestone and a benchmark for efficacy and safety of DES Worldwide. Yukon Choice PC showing the lowest Stent thrombosis rates compared to Xience and Cypher in 10 years creates a strong testimony that this technology is truly next generation in terms of safety,” said Gurmit Singh Chugh, Managing Director (MD) of Translumina Therapeutics, the manufacturer of Yukon Choice PC.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.